Results 191 to 200 of about 3,104,714 (298)

Model‐Informed Evaluation of Hydroxyurea Exposure During Lactation

Clinical Pharmacology &Therapeutics, EarlyView.
Hydroxyurea is a cornerstone therapy for sickle cell anemia; however, evidence guiding its use during lactation remains limited. This study aimed to develop a population pharmacokinetic (PK) model to characterize hydroxyurea disposition in maternal plasma and breast milk, and to quantify infant exposure under clinically relevant breastfeeding scenarios.
Anhar Hosawi, Kei Irie, Min Dong, Julie Ware, Russell Ware, Tomoyuki Mizuno   +5 more
wiley   +1 more source

Cohort profile update: the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC). [PDF]

BMJ Open
Jääskeläinen TJ, Kivelä A, Lokki AI, Kaartokallio T, Kortelainen E, Tyrmi J, Leinonen J, Kajantie E, Kere J, Kivinen K, Pouta A, Heinonen S, Laivuori H, FINNPEC Study Group.   +13 more
europepmc   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Early impact of maternal RSV vaccination on bronchiolitis hospitalisation and critical care admissions in infants under age 3 months, England, September 2024 to March 2026. [PDF]

Euro Surveill
Broad J, Wilson M, Borjas-Howard J, Voysey M, Drysdale SB, Andrews N, Watson CH, Whitaker HJ.   +7 more
europepmc   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Labor Induction Outcomes and Short-Term Safety of Controlled-Release Vaginal Dinoprostone in Women Beyond 36 Weeks of Gestation: A Prospective Observational Study in Vietnam. [PDF]

Int J Womens Health
Nguyen KT, Duong TT, Bui TTT, Bui TM.
europepmc   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu, Zhigang Liu, Xiaohu Kuang, Yueming Wang, Xiaoyi Liu, Jiyuan Ding, Xia Zhou, Xin Zhou, Qianyu Liang, Meizhuo Zhang, Hao Zhao, Qingqing Tan, Weihong Zheng, Huaxin Liao, Charlotte Lemech, Wanmei Wang   +15 more
wiley   +1 more source

Vitamin K2 ameliorates pregnancy- and lactation-associated osteopenia and postpartum depression. [PDF]

Imeta
Yuan W, Hang J, Jia J, Huang J, Zheng X, Wang H, Wu T, Liu H, Zhu J, Zhang C, He J, Zhang Y, Wang H, Xiong X, He N, Bai H, Yan J, Leng H, Zhu W, Xu Y, Shi J, Song C.   +21 more
europepmc   +1 more source

Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model‐Based Analysis of Mother–Infant Pairs for Tuberculosis Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
IMPAACT 2001 (NCT02651259) evaluated the safety and pharmacokinetics (PK) of once‐weekly isoniazid and rifapentine in pregnant and postpartum women for tuberculosis prevention. Rifapentine (RPT) and desacetyl rifapentine (desRPT) PK data were collected in maternal plasma, breast milk, infant cord blood, and infant plasma.
Priya Jayachandran, Jyoti S. Mathad, Nan Zhang, Paula Britto, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Ellen Townley, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Amita Gupta, Kelly E. Dooley, Radojka Savic, on behalf of the IMPAACT 2001 Study Team   +18 more
wiley   +1 more source